Loading stock data…
AbbVie Inc. (ABBV)
$253.68+0.32 (+0.13%)
Market OpenUpdated 11:03 AM EDT
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AbbVie Inc. in the Healthcare sector is trading at $253.68 with a market capitalization of $448.2B. Wall Street consensus targets $254.38 (29 analysts), implying a +0.3% move over the next 12 months. The stock is currently near its 52-week high of $254.70, remaining 15.8% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.00B↓ | $16.62B↑ | $15.78B↑ | $15.42B↑ | $13.34B |
| Gross Profit | $10.78B↓ | $12.07B↑ | $10.47B↓ | $11.08B↑ | $9.34B |
| Operating Income | $4.73B↓ | $5.81B↑ | $4.58B↓ | $5.72B↑ | $3.98B |
| Net Income | $695.00M↓ | $1.82B↑ | $186.00M↓ | $938.00M↓ | $1.29B |
Peer Comparison
JNJUNHPFE
Fundamentals
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$448.19B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
123.74
Beta
Defensive asset. Lower volatility than the S&P 500.
0.31
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.66%
ROE
Average efficiency. Growth may require heavy reinvestment.
-54.61%
Volume
Today's trading volume
2.33M
Recent News
2 S&P 500 Stocks with Promising Prospects and 1 We Find Risky
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Here's Why Shares of Eli Lilly Hit an All-Time High on Friday
LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]
AbbVie (ABBV) Wins Health Canada Approval for Boey
AbbVie Inc. (NYSE:ABBV) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 23, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced that Health Canada approved Boey for the temporary improvement of moderate to severe lines between the eyebrows in adults. Boey is the first and only approved botulinum […]
AbbVie (ABBV) to Acquire Apogee Therapeutics
AbbVie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. AbbVie Inc. (NYSE:ABBV) and Apogee Therapeutics announced on June 22 their entry into a definitive agreement under which AbbVie Inc. (NYSE:ABBV) will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across immunological and inflammatory diseases, which includes […]